Preclinical evaluation of differentially targeting dual virotherapy for human solid cancer

Molecular Cancer Therapeutics

Volumn 9, Issue 6, 2010, Pages 1884-1893

  Sakai, Ryo ^a   Kagawa, Shunsuke ^a,b   Yamasaki, Yasumoto ^a   Kojima, Toru ^a   Uno, Futoshi ^a,b   Hashimoto, Yuuri ^a,c   Watanabe, Yuichi ^a,c   Urata, Yasuo ^c   Tanaka, Noriaki ^a   Fujiwara, Toshiyoshi ^a,b  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^c National Institute of Infectious Diseases   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVEXIN; ANTINEOPLASTIC AGENT; CASPASE 3; OBP 301; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTITUMOR GENE; ARTICLE; CELL CYCLE; CELL DEATH; COPY NUMBER VARIATION; DRUG MECHANISM; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR GROWTH; VIROTHERAPY; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; GENE DOSAGE; HUMANS; MICE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; TRANSDUCTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77953450592     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0205     Document Type: Article

References (33)

1. Grem JL. Biochemical modulation of 5-FU in systemic treatment of advanced colorectal cancer. Oncology (Williston Park) 2001;15:13-9.
2. Kumar S, Gao L, Yeagy B, Reid T. Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther 2008;10:371-9.
3. Senzer N, Mani S, Rosemurgy A, et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor α gene: a phase I study in patients with solid tumors. J Clin Oncol 2004;22:592-601.
4. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
5. Levine AJ, Perry ME, Chang A, et al. The 1993 Walter Hubert lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 1994;69:409-16.
6. Swisher SG, Roth JA, Nemunaitis J, et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:763-71.
7. Nemunaitis J, Swisher SG, Timmons T, et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 2000;18:609-22.
8. Swisher SG, Roth JA, Komaki R, et al. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 2003;9:93-101.
9. Fujiwara T, Tanaka N, Kanazawa S, et al. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2006;24:1689-99.
10. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-6.
11. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997;57:2559-63.
12. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001;7:781-7.
13. Kawashima T, Kagawa S, Kobayashi N, et al. Telomerase-specific replication-selective virotherapy for human cancer. Clin Cancer Res 2004;10:285-92.
14. Umeoka T, Kawashima T, Kagawa S, et al. Visualization of intrathoracically disseminated solid tumors in mice with optical imaging by telomerase-specific amplification of a transferred green fluorescent protein gene. Cancer Res 2004;64:6259-65. (Pubitemid 39129429)
15. Taki M, Kagawa S, Nishizaki M, et al. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD'). Oncogene 2005;24:3130-40. (Pubitemid 40695082)
16. Fujiwara T, Kagawa S, Kishimoto H, et al. Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy. Int J Cancer 2006;119:432-40. (Pubitemid 43911910)
17. Kishimoto H, Kojima T, Watanabe Y, et al. In vivo imaging of lymph node metastasis with telomerase-specific replicationselective adenovirus. Nat Med 2006;12:1213-9.
18. Blackburn EH. Structure and function of telomeres. Nature 1991;350:569-73.
19. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
20. Shay JW, Wright WE. Telomerase activity in human cancer. Curr Opin Oncol 1996;8:66-71.
21. Nakayama J, Tahara H, Tahara E, et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 1998;18:65-8.
22. Fujiwara T, Tanaka N, Numunaitis JJ, et al. Phase I trial of intratumoral administration of OBP-301, a novel telomerase-specific oncolytic virus, in patients with advanced solid cancer: evaluation of biodistribution and immune response. J Clin Oncol 2008;26:3572.
23. Ohtani S, Kagawa S, Tango Y, et al. Quantitative analysis of p53-targeted gene expression and visualization of p53 transcriptional activity following intratumoral administration of adenoviral p53 in vivo. Mol Cancer Ther 2004;3:93-100.
24. Roth JA. Adenovirus p53 gene therapy. Expert Opin Biol Ther 2006;6:55-61.
25. Kirn D. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert Opin Biol Ther 2001;1:525-38.
26. Hall AR, Dix BR, O'Carroll SJ, Braithwaite AW. p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat Med 1998;4:1068-72.
27. Lee CT, Lee YJ, Kwon SY, et al. In vivo imaging of adenovirus transduction and enhanced therapeutic efficacy of combination therapy with conditionally replicating adenovirus and adenovirusp27. Cancer Res 2006;66:372-7.
28. Li X, Raikwar SP, Liu YH, et al. Combination therapy of androgen-independent prostate cancer using a prostate restricted replicative adenovirus and a replication-defective adenovirus encoding human endostatin-angiostatin fusion gene. Mol Cancer Ther 2006;5:676-84.
29. Nemunaitis J, Tong AW, Nemunaitis M, et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther 2010;18:429-34.
30. Chattopadhyay D, Ghosh MK, Mal A, Harter ML. Inactivation of p21 by E1A leads to the induction of apoptosis in DNA-damaged cells. J Virol 2001;75:9844-56.
31. Haviv YS, Takayama K, Glasgow JN, et al. A model system for the design of armed replicating adenoviruses using p53 as a candidate transgene. Mol Cancer Ther 2002;1:321-8.
32. Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Cancer Res 2001;61:8743-50.
33. Hioki M, Kagawa S, Fujiwara T, et al. Combination of oncolytic adenovirotherapy and Bax gene therapy in human cancer xenografted models. Potential merits and hurdles for combination therapy. Int J Cancer 2008;122:2628-33.